Clinical Trial Update: MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating MK-0646 with gemcitabine +/- erlotinib in advanced pancreatic cancer completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gemcitabine (Gemcitabine)
• MK-0646 (dalotuzumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-03-20